Pfizer, Valneva SE report phase 3 results for Lyme vaccine candidate
Source: SeekingAlpha
2026-03-23 07:51:42 ET
Read the full article on Seeking Alpha
For further details see:
Pfizer, Valneva SE report phase 3 results for Lyme vaccine candidate
Valneva SE
NASDAQ: INRLF
INRLF Trading
0.0% G/L:
$2.97 Last:
300 Volume:
$3.04 Open:
INRLF Latest News
March 26, 2026 12:45:00 pm
Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC
March 09, 2026 12:45:00 pm
Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026
INRLF Stock Data
$786,522,915
123,310,055
N/A
122
N/A
Biotechnology & Life Sciences
Healthcare
FR
Lyon
